Mengyuan Cai

Rotterdam, ZH 3015GD, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Pharmacovigilance of carmustine: distinct neurotoxic and systemic safety signals identified in FAERS.

Pharmacovigilance of carmustine: distinct neurotoxic and systemic safety signals identified in FAERS.

Journal: BMC cancer
Published: April 25, 2026

Pharmacovigilance evaluation of somatrogon-associated adverse events in real-world databases.

Pharmacovigilance evaluation of somatrogon-associated adverse events in real-world databases.

Journal: Endocrine connections
Published: April 24, 2026

Comprehensive Pharmacovigilance Assessment of Pegvisomant-Associated Adverse Events Using the FDA Adverse Event Reporting System and World Health Organization VigiAccess Databases.

Comprehensive Pharmacovigilance Assessment of Pegvisomant-Associated Adverse Events Using the FDA Adverse Event Reporting System and World Health Organization VigiAccess Databases.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: January 03, 2026

C-reactive protein-triglyceride-glucose index and risk of incident depressive symptoms in older adults: an eight-year follow-up study from ELSA.

C-reactive protein-triglyceride-glucose index and risk of incident depressive symptoms in older adults: an eight-year follow-up study from ELSA.

Journal: Annals of general psychiatry
Published: December 27, 2025

Ageing and Inequality Drive the Global Burden of Low Bone Mineral Density in Midlife and Older Women.

Ageing and Inequality Drive the Global Burden of Low Bone Mineral Density in Midlife and Older Women.

Journal: Calcified tissue international
Published: December 23, 2025

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.

Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: October 17, 2025

Frailty and oral health among middle-aged and older adults: findings from the English longitudinal study of ageing.

Frailty and oral health among middle-aged and older adults: findings from the English longitudinal study of ageing.

Journal: BMC oral health
Published: October 01, 2025

Higher sleep quality predicts lower risk of depressive symptoms: A prospective analysis from the English longitudinal study of ageing.

Higher sleep quality predicts lower risk of depressive symptoms: A prospective analysis from the English longitudinal study of ageing.

Journal: Journal of affective disorders
Published: August 10, 2025

Multifaceted safety concerns of glibenclamide in managing type 2 diabetes: Evidence from real-world adverse event analysis.

Multifaceted safety concerns of glibenclamide in managing type 2 diabetes: Evidence from real-world adverse event analysis.

Journal: European journal of pharmacology
Published: July 13, 2025

Post-marketing safety profile of Ertugliflozin: Insights from a real-world pharmacovigilance analysis based on the FAERS database.

Post-marketing safety profile of Ertugliflozin: Insights from a real-world pharmacovigilance analysis based on the FAERS database.

Journal: European journal of pharmacology
Published: June 22, 2025

Good sleep quality predicts a lower risk of osteoporosis in older adults: Evidence from the English longitudinal study of ageing.

Good sleep quality predicts a lower risk of osteoporosis in older adults: Evidence from the English longitudinal study of ageing.

Journal: Experimental gerontology
Published: May 25, 2025

Skin Advanced Glycation End Products (AGEs) are not associated with bone mineral density longitudinally: The Rotterdam Study.

Skin Advanced Glycation End Products (AGEs) are not associated with bone mineral density longitudinally: The Rotterdam Study.

Journal: Bone
Published: May 20, 2025
Showing 1-12 of 13

Last Updated: 09/26/2026